Eurofins: nine-month sales growth of almost 7%
(CercleFinance.com) - Eurofins Scientific reports 9m 2024 sales of E5.
14bn, up 6.7%, including organic growth of 5.2% for its core business (i.e. excluding Covid-19-related revenues).
Despite the volatile and more challenging environment in BioPharma and Agrosciences, Eurofins' businesses continued to deliver solid results, the bioanalytical services provider said.
Regarding its outlook, Eurofins confirms its 2024 adjusted EBITDA target of E1.525bn and E1.575bn, although lowers its sales forecast to close to E7bn (from E7.075bn to E7.175bn).
In addition, the group states that a cash audit confirms its cash balance for 2023 and the high integrity of its systems and controls, and refutes Muddy Waters allegations of real estate transactions that took place between 10 and 20 years ago.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
14bn, up 6.7%, including organic growth of 5.2% for its core business (i.e. excluding Covid-19-related revenues).
Despite the volatile and more challenging environment in BioPharma and Agrosciences, Eurofins' businesses continued to deliver solid results, the bioanalytical services provider said.
Regarding its outlook, Eurofins confirms its 2024 adjusted EBITDA target of E1.525bn and E1.575bn, although lowers its sales forecast to close to E7bn (from E7.075bn to E7.175bn).
In addition, the group states that a cash audit confirms its cash balance for 2023 and the high integrity of its systems and controls, and refutes Muddy Waters allegations of real estate transactions that took place between 10 and 20 years ago.
Copyright (c) 2024 CercleFinance.com. All rights reserved.